Sol-Gel Technologies (4SG) Price & Analysis

0 Followers

4SG Stock Chart & Stats

€63.50

€0.37(41.71%)

At close: Jan 08 4:00 PM EST

€63.50

€0.37(41.71%)

Day’s Range― - ―

52-Week Range€8.95 - €82.00

Previous CloseN/A

Volume1.00K

Average Volume (3M)15.00

Market Cap

€234.75M

Enterprise Value€172.77

Total Cash (Recent Filing)€30.47M

Total Debt (Recent Filing)€1.39M

Price to Earnings (P/E)―

Beta1.73

Next Earnings

Jul 30, 2026

EPS Estimate

-2.07

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.54

Shares Outstanding3,268,991

10 Day Avg. Volume46

30 Day Avg. Volume15

Financial Highlights & Ratios

PEG Ratio-0.04

Price to Book (P/B)5.15

Price to Sales (P/S)6.06

P/FCF Ratio426.90

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€169.10

Price Target Upside166.31% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-7.97

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Extended Patidegib IP To 2044A U.S. notice of allowance extending SGT-610 method-of-use protection to 2044 creates durable exclusivity for the lead asset. This lengthens commercialization and royalty windows, strengthens bargaining power with partners, and supports long-term value capture from a pivotal dermatology program.

Raised $33.1M To Extend Cash RunwayAn oversubscribed $33.1M equity raise materially extends runway into Q1 2028, reducing near-term financing risk. This funding supports late-stage trials, regulatory prep and commercialization steps, enabling the company to pursue milestones and partnerships without immediate cash pressure.

Revenue Rebound, Positive Cash Flow, Low LeverageA sharp 2025 revenue rebound with near-equal gross profit and modest positive operating/free cash flow, combined with very low debt, indicates improving commercial traction and conservative financing. If sustained, these dynamics support operational autonomy and lower funding dependence long term.

Bears Say

Still Loss-making (2025 Net And Operating Losses)Despite revenue recovery, the business remained loss-making in 2025 with sizable EBIT and net losses. Continued operating deficits mean profitability is not yet proven, risking renewed cash strain if revenue or margins falter and limiting reinvestment capacity over the medium term.

Shrinking Equity Base From Cumulative LossesA declining shareholders' equity balance signals sustained historical losses that have eroded the capital base. This weakens financial cushions, could impair borrowing capacity, and leaves the company more exposed if future setbacks require additional capital or dilution.

Historic Cash Burn And Margin VolatilityPrior multi-year cash burn and extreme margin swings create a structural risk: the 2025 cash-flow improvement must be sustained to avoid returning to heavy cash consumption. Persistent margin volatility complicates forecasting and increases dependency on periodic financing or partner milestones.

Sol-Gel Technologies News

What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity

WSW, NY, July 22nd, 2026, FinanceWire Ten billion dollars. That is what Vertex Pharmaceuticals (Nasdaq:VRTX) agreed to pay...

5d ago

PTN

CRNX

Sol-Gel Technologies initiated with an Outperform at Mizuho

Mizuho initiated coverage of Sol-Gel Technologies (SLGL) with an Outperform rating and $285 price target The firm sees...

1M ago

SLGL

Sol-Gel Technologies initiated with a Buy at TD Cowen

TD Cowen analyst Stacy Ku initiated coverage of Sol-Gel Technologies (SLGL) with a Buy rating and no price...

2M ago

SLGL

Analyst Maintains Buy on Sol-Gel, Citing SGT-610 Progress and Solid Cash Runway with Unchanged $184 Price Target

Sol-Gel Technologies, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Patrick Dolezal from...

2M ago

SLGL

Sol-Gel Technologies reports Q1 EPS ($1.31) vs. ($3.20) last year

Reports Q1 revenue $108,000 vs. $1.03M last year. Mori Arkin, executive chairman of Sol-Gel, stated: “The first quarter...

2M ago

SLGL

Sol-Gel Extends Patidegib IP to 2044 and Bolsters Cash Runway With $33.1 Million Offering

Sol-Gel Technologies ( ($SLGL) ) just unveiled an announcement. In the first quarter of 2026, Sol-Gel Technologies secured...

2M ago

SLGL

Sol-Gel Technologies Prices $33.1 Million Oversubscribed Equity Offering to Advance SGT-610

Sol-Gel Technologies ( ($SLGL) ) has provided an update. On March 23, 2026, Sol-Gel Technologies entered into an...

4M ago

SLGL

Sol-Gel Technologies 459K share Spot Secondary priced at $72.00

TD Cowen and LifeSci Capital are acting as joint book running managers for the offering. Published first on...

4M ago

SLGL

Sol Gel Technologies trading resumes

09:48 EDT Sol Gel Technologies trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

5M ago

SLGL

Sol Gel Technologies trading halted, volatility trading pause

09:38 EDT Sol Gel Technologies trading halted, volatility trading pause Published first on TheFly – the ultimate source...

5M ago

SLGL

Sol-Gel Technologies: Upside-Driven Buy on SGT-610’s Orphan Gorlin Syndrome Opportunity and Repriced Peak Sales Potential

In a report released today, Ram Selvaraju from H.C. Wainwright maintained a Buy rating on Sol-Gel Technologies, with...

6M ago

SLGL

Sol-Gel Technologies price target raised to $110 from $50 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Sol-Gel Technologies (SLGL) to $110 from $50 and keeps a...

6M ago

SLGL

Sol-Gel: SGT-610 as Core Value Driver Underpins $50 Target and Buy Rating Despite Pipeline Setbacks

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Sol-Gel Technologies, with...

7M ago

SLGL

Sol-Gel Technologies Updates Clinical Pipeline Following Phase 1b Results

Sol-Gel Technologies ( ($SLGL) ) has provided an update. On December 17, 2025, Sol-Gel Technologies announced that its...

7M ago

SLGL

4SG FAQ

What was Sol-Gel Tech’s price range in the past 12 months?

Sol-Gel Tech lowest stock price was €8.95 and its highest was €82.00 in the past 12 months.

What is Sol-Gel Tech’s market cap?

Sol-Gel Tech’s market cap is €234.75M.

When is Sol-Gel Tech’s upcoming earnings report date?

Sol-Gel Tech’s upcoming earnings report date is Jul 30, 2026 which is in 2 days.

How were Sol-Gel Tech’s earnings last quarter?

Sol-Gel Tech released its earnings results on May 08, 2026. The company reported €1.148 earnings per share for the quarter, beating the consensus estimate of -€2.506 by €3.654.

Is Sol-Gel Tech overvalued?

According to Wall Street analysts Sol-Gel Tech’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sol-Gel Tech pay dividends?

Sol-Gel Tech does not currently pay dividends.

What is Sol-Gel Tech’s EPS estimate?

Sol-Gel Tech’s EPS estimate is -2.07.

How many shares outstanding does Sol-Gel Tech have?

Sol-Gel Tech has 3,268,991 shares outstanding.

What happened to Sol-Gel Tech’s price movement after its last earnings report?

Sol-Gel Tech reported an EPS of €1.148 in its last earnings report, beating expectations of -€2.506. Following the earnings report the stock price went down -0.855%.

Which hedge fund is a major shareholder of Sol-Gel Tech?

Currently, no hedge funds are holding shares in DE:4SG

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Sol-Gel Technologies Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

116.35%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sol-Gel Tech

Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.

Sol-Gel Technologies (4SG) Earnings & Revenues

Historic Earnings Reports

4SG Stock 12 Month Forecast

Average Price Target

€169.10

▲(166.31% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"€5","250":"€250","66.25":"€66.3","127.5":"€127.5","188.75":"€188.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":249.71414430000002,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€249.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":169.10466614,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€169.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":96.3808978,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€96.38</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,66.25,127.5,188.75,250],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60,74.59339571538462,89.18679143076923,103.78018714615385,118.37358286153847,132.96697857692308,147.5603742923077,162.15377000769232,176.74716572307693,191.34056143846155,205.93395715384617,220.52735286923078,235.1207485846154,{"y":249.71414430000002,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60,68.39266662615384,76.7853332523077,85.17799987846155,93.57066650461539,101.96333313076923,110.35599975692308,118.74866638307694,127.14133300923078,135.53399963538462,143.92666626153846,152.31933288769233,160.71199951384617,{"y":169.10466614,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60,62.7985306,65.5970612,68.3955918,71.1941224,73.992653,76.7911836,79.5897142,82.3882448,85.1867754,87.985306,90.7838366,93.5823672,{"y":96.3808978,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.05,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":10.6,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":18.7,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":23.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":58,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.5,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >